NCT01763398View on ClinicalTrials.gov

Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study

CompletedOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Non-Hodgkin's Lymphoma

Trial Locations (1)

120-752

Severance Hospital, Seoul

Sponsors

Collaborators (1)

JW Pharmaceutical

All Listed Sponsors

collaborator

JW Pharmaceutical

INDUSTRY

lead

Yonsei University

OTHER

NCT01763398 - Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study | Biotech Hunter | Biotech Hunter